for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aerpio Pharmaceuticals Inc

ARPO.OQ

Latest Trade

1.20USD

Change

-0.02(-1.64%)

Volume

113,681

Today's Range

1.19

 - 

1.22

52 Week Range

0.42

 - 

2.31

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.22
Open
1.21
Volume
113,681
3M AVG Volume
47.49
Today's High
1.22
Today's Low
1.19
52 Week High
2.31
52 Week Low
0.42
Shares Out (MIL)
47.11
Market Cap (MIL)
56.53
Forward P/E
-8.57
Dividend (Yield %)
--

Next Event

Aerpio Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Aerpio Announces Statistically Significant Topline Results From Razuprotafib Glaucoma Phase 2 Trial

Aerpio Pharmaceuticals Reports Q3 Loss Per Share $0.12

Aerpio Pharmaceuticals Q2 Earnings Per Share $0.23

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aerpio Pharmaceuticals Inc

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is AKB-9778. AKB-9778 works by inhibiting VE-PTP, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The Company is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The Company’s pipeline includes the humanized monoclonal antibody, ARP-1536, directed at the same target as subcutaneous AKB-9778.

Industry

Biotechnology & Drugs

Contact Info

9987 Carver Rd

BLUE ASH, OH

45242-5550

United States

+1.513.9851920

https://aerpio.com/

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-0.310

2019

-0.570

2020(E)

-0.140
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.77
Price To Book (MRQ)
1.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-9.06
Return on Equity (TTM)
-8.48

Latest News

Latest News

BRIEF-Aerpio Pharmaceuticals Says On June 11 It Got Notice From Nasdaq Of Regaining Compliance

* AERPIO PHARMACEUTICALS - ON JUNE 11, CO GOT NOTICE FROM NASDAQ OF REGAINING COMPLIANCE Source text: [ID:https://bit.ly/2Nszmz9] Further company coverage:

BRIEF-Aerpio And Quantum Leap Announce Selection Of Razuprotafib For Testing in COVID-19 Trial

* AERPIO PHARMACEUTICALS, INC. AND QUANTUM LEAP HEALTHCARE COLLABORATIVE ANNOUNCE THE SELECTION OF RAZUPROTAFIB FOR EVALUATION IN THE I-SPY COVID TRIAL FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN COVID-19 PATIENTS

BRIEF-Aerpio Pharmaceuticals Says Announced Restructuring Of Licensing Deal With Unit Of Gossamer Bio

* AERPIO ANNOUNCES AMENDED LICENSING DEAL WITH GOSSAMER BIO ON ITS INFLAMMATORY BOWEL DISEASE (IBD) PRODUCT CANDIDATE GB004 (FORMERLY AKB-4924)

BRIEF-Aerpio Pharmaceuticals Reports Q1 Financial Results

* AERPIO REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aerpio Pharmaceuticals Reports Q4 Loss Per Share Of $0.11

* AERPIO REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up